Tag: AptaTargets
AptaTargets announces publication of APRIL trial data in JAMA Neurology
As per a press release from AptaTargets, JAMA Neurology has published positive results from APRIL—a Phase 1b/2a clinical trial evaluating the safety and efficacy...
Neuroprotective agent linked to reduced death and disability in ischaemic stroke...
ApTOLL, a neuroprotectant medication intended to shield the brain from tissue damage, has been linked to reduced death and disability when used alongside standard...
